Tag Archives | M&A

Rayno Life Science Portfolio Flash Update: Roche and FMI Merger; Update with XBI breakout

source Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50 in the pre-market. We added FMI to our top picks on […]

Continue Reading 0

Slower Growth in Diagnostics Stocks Except for NexGen Sequencing and Molecular

where to buy prednisone steroid New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing  sales and earnings growth vs forecasts. Rayno Clinical Diagnostics Portfolio Update We initiated coverage of Clinical Diagnostic and Life Science Tools stocks in […]

Continue Reading 0

Mid Cap Emerging Biopharmaceutical Companies: Valuations Do Matter for M&A

http://truecom.com/news-sitemap.xml Update-1… On Onyx $10.4B Buyout By Amgen (AMGN) Valuation Models for  Biopharma Stocks -M&A Update In October 2013 we compared emerging biotech stocks after the acquisition of Onyx Pharmaceuticals by Amgen (AMGN). Now that rumors are “out there” for the acquisition of Pharmacyclics (PCYC) by large healthcare companies such as Johnson and Johnson (JNJ) and […]

Continue Reading 0